Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial
DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic
HNSCC.